Skip to main content

Table 2 Correlations between circDDX17 expression and clinicopathological parameters in CRC patients

From: RNA sequencing reveals the expression profiles of circRNA and indicates that circDDX17 acts as a tumor suppressor in colorectal cancer

Clinicopathological Total (n = 60) CircDDX17 expressiona p value
parameters Low (%) High (%)
Gender
 Male 35 20(57.1%) 15(42.9%) 0.315
 Female 25 11(44.0%) 14(56.0%)  
Age(years)
 ≤ 65 26 12(46.2%) 14(53.8%) 0.455
 > 65 34 19(55.9%) 15(44.1%)  
Tumor site
 Colon 37 17(45.9%) 20(54.1%) 0.426
 Rectum 23 13(56.5%) 10(43.5%)  
Tumor size(cm)
 ≤ 5 36 17(47.2%) 19(52.8%) 0.598
 > 5 24 13(54.2%) 11(45.8%)  
Lymphovascular invasion
 Absent 22 7(31.8%) 15 (68.2%) 0.011*
 Present 38 25(65.8%) 13(34.2%)  
Differentiation
 Well-moderate 42 19(45.2%) 23(54.8%) 0.464
 Poor 18 10(55.6%) 8(44.4%)  
Depth of invasion
 T1-T2 21 7(33.3%) 14(66.7%) 0.007**
 T3-T4 39 27(69.2%) 12(30.8%)  
Lymph node metastasis
 N0 27 9(33.3%) 18(66.7%) 0.020*
 N1-N2 33 21(63.6%) 12(36.4%)  
Distant metastasis
 M0 43 15(34.9%) 28(65.1%) 0.012*
 M1 17 12(70.6%) 5(29.4%)  
TNM stage
 I-II 26 10(38.5%) 16 (61.5%) 0.024*
 III-IV 34 23(67.6%) 11(32.4%)  
  1. *p < 0.05
  2. **p < 0.01
  3. aUsing median expression level of circDDX17 as cutoff